STAAR Surgical (NASDAQ:STAA) Major Shareholder Broadwood Partners, L.P. Buys 259,316 Shares

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 259,316 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were bought at an average cost of $17.05 per share, for a total transaction of $4,421,337.80. Following the completion of the acquisition, the insider now directly owns 11,548,753 shares in the company, valued at $196,906,238.65. The trade was a 2.30 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was bought at an average cost of $16.64 per share, with a total value of $4,151,729.92.
• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The shares were bought at an average cost of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. purchased 259,616 shares of STAAR Surgical stock. The stock was purchased at an average price of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. acquired 8,221 shares of STAAR Surgical stock. The shares were purchased at an average price of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The shares were purchased at an average cost of $21.46 per share, for a total transaction of $453,986.30.
• On Wednesday, December 18th, Broadwood Partners, L.P. purchased 23,000 shares of STAAR Surgical stock. The shares were purchased at an average price of $24.33 per share, for a total transaction of $559,590.00.
• On Monday, December 16th, Broadwood Partners, L.P. acquired 53,500 shares of STAAR Surgical stock. The stock was acquired at an average price of $24.24 per share, with a total value of $1,296,840.00.

STAAR Surgical Trading Up 2.4 %

STAA stock opened at $18.17 on Thursday. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68. The stock has a 50-day moving average price of $21.41 and a 200-day moving average price of $27.04. The firm has a market cap of $896.24 million, a PE ratio of -44.32 and a beta of 0.66.

Analysts Set New Price Targets

Several brokerages have issued reports on STAA. Mizuho cut shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $45.00 to $17.00 in a research report on Wednesday, February 12th. Canaccord Genuity Group decreased their price objective on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a report on Thursday, February 13th. William Blair lowered STAAR Surgical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 12th. StockNews.com lowered STAAR Surgical from a “hold” rating to a “sell” rating in a research report on Thursday, February 13th. Finally, Stephens restated an “equal weight” rating and set a $28.00 price objective on shares of STAAR Surgical in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $26.86.

Hedge Funds Weigh In On STAAR Surgical

Institutional investors and hedge funds have recently modified their holdings of the business. Resona Asset Management Co. Ltd. bought a new stake in shares of STAAR Surgical in the 4th quarter valued at $36,411,000. Vanguard Group Inc. lifted its stake in STAAR Surgical by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock valued at $142,232,000 after acquiring an additional 319,441 shares in the last quarter. Yunqi Capital Ltd lifted its position in shares of STAAR Surgical by 48.9% during the fourth quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier’s stock valued at $18,640,000 after purchasing an additional 252,113 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of STAAR Surgical by 411.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock worth $7,978,000 after buying an additional 172,779 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in STAAR Surgical by 25.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 853,370 shares of the medical instruments supplier’s stock worth $20,728,000 after purchasing an additional 171,046 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.